Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current

News

Halozyme Therapeutics: Q2 Earnings Insights

Author: Benzinga Insights | August 09, 2022 11:50pm

 

Halozyme Therapeutics (NASDAQ:HALO) reported its Q2 earnings results on Tuesday, August 9, 2022 at 04:00 PM.

Here's what investors need to know about the announcement.

Earnings

Halozyme Therapeutics beat estimated earnings by 6.0%, reporting an EPS of $0.53 versus an estimate of $0.5.

Revenue was up $15.91 million from the same period last year.

Past Earnings Performance

Last quarter the company missed on EPS by $0.02 which was followed by a 0.99% increase in the share price the next day.

Here's a look at Halozyme Therapeutics's past performance:

 

Quarter Q1 2022 Q4 2021 Q3 2021 Q2 2021
EPS Estimate 0.49 0.41 0.42 0.40
EPS Actual 0.47 0.42 0.55 0.66
Revenue Estimate 128.25M 100.32M 101.94M 103.16M
Revenue Actual 117.28M 102.00M 115.83M 136.46M

New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).

Guidance

Halozyme Therapeutics management provided guidance for FY 2022, expecting earnings between $2.1 and $2.25 per share.

To track all earnings releases for Halozyme Therapeutics visit their earnings calendar here.

This article was generated by Benzinga's automated content engine and reviewed by an editor.

Posted In: HALO

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist